Evosep

Evosep develops new solutions to make clinical proteomics 100 times more robust and 10 times faster. They are targeting the growing need for throughput with robust solutions for clinical and large-scale proteomics, and they have a very ambitious business plan to bring their first products to market. They are basing their design on years of experience with nano-UHPLC R&D and application support, critically rethinking the necessary system architectures for successful sample separation before mass spectrometric analysis. Evosep aims to improve quality of life and patient care by radically innovating how protein based clinical diagnostics are performed, initially through collaborations with world-leading scientists about developing new technologies and solutions to make sample separation 10 times faster and 100 times more robust than todays’alternatives. Proteomics is about the study of proteins in a biological mechanism, both their individual function and their combined interactions. For clinical proteomics the goal is to be able to quickly and efficiently compare a biological sample against a profile panel of selected proteins in order to deliver a diagnose / verdict of healthy or diseased (within given statistical margins). Such a profile is typically called a biomarker and for official approval, it must be demonstrated successfully on a large population. This calls for fast sample processing and because such clinical samples, in the form of blood or biopsies, are much more crude that the relatively clean cell cultures used in basic research, very robust protocols and consumables are also required.

Domain

evosep.com

Country

Germany

Industry

Biotechnology

Employees

51-100

Last Funding

$40.0M

Founded

2015